tetano
Editor, Senior Moderator
Sci Rep. 2016 Feb 12;6:20725. doi: 10.1038/srep20725.
[h=1]Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients - an 18-week, open-label trial.[/h] Chang YT[SUP]1,[/SUP][SUP]2[/SUP], Wang JR[SUP]3,[/SUP][SUP]4[/SUP], Lin MT[SUP]5[/SUP], Wu CJ[SUP]2,[/SUP][SUP]4[/SUP], Tsai MS[SUP]5[/SUP], Wen-Chi CL[SUP]5[/SUP], Shih TE[SUP]5[/SUP], Kuo TH[SUP]2[/SUP], Song EJ[SUP]6[/SUP], Sung JM[SUP]2,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011-2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3-9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6-82.5% in the adult (18-60 years) and 33.3-66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0-25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0-33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered.
PMID: 26869526 [PubMed - in process] Free full text
[h=1]Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients - an 18-week, open-label trial.[/h] Chang YT[SUP]1,[/SUP][SUP]2[/SUP], Wang JR[SUP]3,[/SUP][SUP]4[/SUP], Lin MT[SUP]5[/SUP], Wu CJ[SUP]2,[/SUP][SUP]4[/SUP], Tsai MS[SUP]5[/SUP], Wen-Chi CL[SUP]5[/SUP], Shih TE[SUP]5[/SUP], Kuo TH[SUP]2[/SUP], Song EJ[SUP]6[/SUP], Sung JM[SUP]2,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011-2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3-9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6-82.5% in the adult (18-60 years) and 33.3-66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0-25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0-33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered.
PMID: 26869526 [PubMed - in process] Free full text